talazoparib
Selected indexed studies
- Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial. (Lancet, 2023) [PMID:37285865]
- Talazoparib. (, 2012) [PMID:31643933]
- Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation. (N Engl J Med, 2018) [PMID:30110579]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial. (2025) pubmed
- Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial. (2023) pubmed
- Talazoparib. (2012) pubmed
- Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation. (2018) pubmed
- First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial. (2024) pubmed
- Talazoparib. (2006) pubmed
- Talazoparib to treat BRCA-positive breast cancer. (2019) pubmed
- Talazoparib for the treatment of prostate cancer. (2024) pubmed
- Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial. (2020) pubmed
- Talazoparib: First Global Approval. (2018) pubmed